POPULARITY
71 episodes with mdprofessor
26 episodes with mdprofessor
20 episodes with mdprofessor
17 episodes with mdprofessor
6 episodes with mdprofessor
5 episodes with mdprofessor
4 episodes with mdprofessor
4 episodes with mdprofessor
2 episodes with mdprofessor
In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers.Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, neuropathy, and cytopenia across ADCsOn-Target vs Off-Target Effects: How linker design, payload type, and drug-to-antibody ratio (DAR) contribute to toxicityCombination Therapy Considerations: Challenges in combining ADCs with immunotherapy or chemotherapy due to overlapping toxicities and tolerability concerns Presenters:Catherine Fahey, MD, PhDAssistant ProfessorDivision of OncologyUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaAlexandra Leary, MD, PhDPresident, GINECO GroupCo-Director, Department of Medical OncologyMedical Oncologist GynecologyTeam Leader, Gynecologic Translational Research Lab, INSERM u981Institut Gustave RoussyVillejuif, FranceFunda Meric-Bernstam, MDChair, Department of Investigational Cancer TherapeuticsMedical Director, Institute for Personalized Cancer TherapyNellie B. Connally Chair in Breast CancerThe University of Texas MD Anderson Cancer CenterHouston, TexasZev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaLink to full program: https://bit.ly/42iEDjVTo claim credit for listening to this episode, please visit the podcast online at the link above.
Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including:Strategies to better identify patients presenting with features of SM to facilitate timely diagnosisCurrent guideline-recommended treatment approachesEmerging data on new targeted agents for SMPharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education)PresentersJonathan A. Bernstein, MDProfessor of MedicineDivision of Rheumatology, Allergy and ImmunologyDepartment of Internal MedicineUniversity of Cincinnati College of MedicinePartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center, LLCCincinnati, OhioRyan Haumschild, PharmD, MS, MBA, CPELVice President of Pharmacy, AmbulatoryEmory HealthcareWinship Cancer InstituteAtlanta, GeorgiaFull link to program page:https://bit.ly/3HcA8z2
In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers.Mechanisms of action of ADCs: how ADCs selectively deliver potent chemotherapy to tumor cellsClinical data across tumor types: highlights from recent trials with trastuzumab deruxtecan and exploration of emerging data on agents such as disitamab vedotinChallenges and future directions:key considerations for combining HER2-targeted ADCs with immunotherapy or chemotherapy, and sequencing ADC therapiesPresenters:Catherine Fahey, MD, PhDAssistant ProfessorDivision of OncologyUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaAlexandra Leary, MD, PhDPresident, GINECO GroupCo-Director, Department of Medical OncologyMedical Oncologist GynecologyTeam Leader, Gynecologic Translational Research Lab, INSERM u981Institut Gustave RoussyVillejuif, FranceFunda Meric-Bernstam, MDChair, Department of Investigational Cancer TherapeuticsMedical Director, Institute for Personalized Cancer TherapyNellie B. Connally Chair in Breast CancerThe University of Texas MD Anderson Cancer CenterHouston, TexasZev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaLink to full program:https://bit.ly/42iEDjVTo claim credit for listening to this episode, please visit the podcast online at the link above.
In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3Overview of the structure of antibody-drug conjugates (ADCs)Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLCData from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLCAn overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLCEarly phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093Program faculty:Lauren Byers, MDProfessor and Thoracic Section ChiefDepartment of Thoracic/Head and Neck Medical OncologyMD Anderson Cancer CenterHouston, TexasChristine L. Hann, MD, PhDAssociate Professor of OncologyDirector, Small Cell Lung Cancer TherapeuticsJohns Hopkins University School of MedicineBaltimore, Maryland
In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how to test for HER2 in advanced cancers and how these tests guide therapy selectionVariability in HER2 Expression Across Tumor Types: Insights into the heterogeneity of HER2 expression and amplification in different cancersChallenges in Standardizing HER2 Testing: The complexities of scoring and testing HER2 in different cancers and institutions, and the need for better harmonization of guidelines and approachesPresenters:Zev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaFunda Meric-Bernstam, MDChair, Department of Investigational Cancer TherapeuticsMedical Director, Institute for Personalized Cancer TherapyNellie B. Connally Chair in Breast CancerThe University of Texas MD Anderson Cancer CenterHouston, TexasAlexandra Leary, MD, PhDPresident, GINECO GroupCo-Director, Department of Medical OncologyMedical Oncologist GynecologyTeam Leader, Gynecologic Translational Research Lab, INSERM u981Institut Gustave RoussyVillejuif, FranceCatherine Fahey, MD, PhDAssistant ProfessorDivision of OncologyUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaLink to full program:https://bit.ly/42iEDjVTo claim credit for listening to this episode, please visit the podcast online at the link above.
In this episode, Chloe Orkin, MBChB, FRCP, MD, and Jean-Michel Molina, MD, PhD, discuss highlights from CCO's independent conference coverage of CROI 2025, including:Advances in HIV treatment based on results from CARESPotential HIV therapies in the pipeline, such as doravirine/islatravirEffects of broadly neutralizing antibodies on HIV treatment and cure Key clinical data on HIV and STI prevention obtained from PILLAR, HPTN 083, PURPOSE 1, and STOMPPresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationHonorary Consultant Physician, Barts Health NHS TrustFaculty of Medicine and DentistryQueen Mary University of LondonLondon, United KingdomJean-Michel Molina, MD, PhDProfessor of MedicineUniversity of Paris CiteDepartment of Infectious DiseasesSaint-Louis and Lariboisiere Hospitals, APHPParis, FranceLink to full program:bit.ly/3E1bAYQTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau, use an illustrative patient case to explore the roles of ALP and other biochemical markers in PBC management, and explain what to expect from treatment. Topics covered include: How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelparPotential outcomes if ALP normalization cannot be achievedThe importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical responsePresenters:Stuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.
Hereditary angioedema (HAE) is a rare condition often due to reduced levels C1-inhibitor, which is a protein involved in various physiological processes in plasma, most notably with the complement system. C1-inhibitor also binds and inhibits plasma kallikrein and factor XIa, thereby affecting bradykinin production. It is believed that the disruptions of these processes cause fluid to leak from the blood to connective tissue, leading to HAE attacks. Owing to its rarity, HAE is often poorly recognized, leading to misdiagnoses and significant diagnostic delays. Being aware of the early signs and symptoms of this condition can lead to faster diagnosis and the use of effective therapies.This program is supported by independent medical education grants from Takeda. To earn CME credit please visit https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/lessons/consider-rare-suspecting-and-diagnosing-hereditary-angioedema-module/ Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in primary care, pediatrics, emergency care, otolaryngology, gastroenterology, and dermatology .Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:- Describe the early symptoms of HAE and its clinical relevance.- Apply best practices to diagnose HAE more efficiently to reduce diagnostic delays. Faculty Jonathan A Bernstein, MDProfessor of MedicineUniversity of Cincinnati Department of Internal MedicineDivision of Immunology, Allergy SectionPartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Bernstein discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomarinGrant/Research Support: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomariSpeaker's Bureau: PharmingPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
Conversations in IFN-y explores the latest advancements in understanding and managing secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with updates from ASH 2024. Featuring discussions by leading experts, the educational activity covers breakthroughs in diagnostic technologies. Topics covered include AI-based histology models and PET/CT imaging, therapeutic innovations such as emapalumab and reduced-intensity conditioning for HSCT. The implications of these findings for improving outcomes in diverse patient populations, including malignancy- and pregnancy-associated HLH will also be discussed.Launch Date: January 9, 2025Release Date: January 9, 2025Expiration Date: December 31, 2025FACULTYPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterAlexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.
In this Conversations in IFN-y podcast episode, emerging data from the 2024 ACR meeting is discussed, highlighting advancements in understanding genetic drivers, cytokine dynamics, and biomarkers like IL-18 and CXCL9 for improved diagnosis and monitoring. Expert insights explore new findings on liver and lung pathology in MAS, as well as updates on therapeutic innovations, including JAK inhibitors and emapalumab, and their roles in enhancing patient outcomes. Practical strategies are provided for integrating the latest research and cutting-edge diagnostics into clinical practice.Launch Date: December 19, 2024Release Date: December 19, 2024Expiration Date: November 30, 2025FACULTYPui Lee, MDAssistant Professor of PediatricsBoston Children's HospitalAlexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.
Clinical gaps in the treatment of pruritus in primary biliary cholangitis (PBC) remain. In this episode, taken from a recent symposium, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss emerging therapies currently in clinical trials for the management of this disease that can dramatically affect patients' quality of life.Listen as they discuss:Gaps in current managementPatient perspectives: why we should not dismiss itching as an underlying psychologic problemPPAR agonists and how they affect pruritusBEZURSO and FITCH ELATIVEENHANCE and RESPONSEIBATs (inhibitors of bile acid transport)GLIMMERCommon questionsPresenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBCLink to full program: https://bit.ly/3Dnfb2E
Although there is currently no FDA-approved treatment for pruritus in primary biliary cholangitis (PBC), symptoms can be mitigated with nonpharmacologic or pharmacologic agents. In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss the clinical management of pruritus in PBC, including:Pruritus assessment toolsOptimal use of tools, including frequency of assessmentCurrent management of pruritusNonpharmacologic interventionsPharmacologic agentsStrategies to optimize assessment and management of pruritusCollaborative careDevelopment of a treatment planOngoing assessment and adjustment of therapyResources and support for patientsPresenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBCLink to full program: https://bit.ly/3Dnfb2E
In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with primary biliary cholangitis (PBC), discuss the burden of pruritus in PBC and the impact it has on quality of life, including both physical and mental health, from a patient's perspective.Presenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBCLink to full program: https://bit.ly/4gDGDaB
Clinical gaps in the treatment of pruritus in primary biliary cholangitis (PBC) remain. In this episode, taken from a recent symposium, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss emerging therapies currently in clinical trials for the management of this disease that can dramatically affect patients' quality of life.Listen as they discuss:Gaps in current managementPatient perspectives: why we should not dismiss itching as an underlying psychologic problemPPAR agonists and how they affect pruritusBEZURSO and FITCH ELATIVEENHANCE and RESPONSEIBATs (inhibitors of bile acid transport)GLIMMERCommon questionsPresenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBCLink to full program: https://bit.ly/3Dnfb2E
Although there is currently no FDA-approved treatment for pruritus in primary biliary cholangitis (PBC), symptoms can be mitigated with nonpharmacologic or pharmacologic agents. In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss the clinical management of pruritus in PBC, including:Pruritus assessment toolsOptimal use of tools, including frequency of assessmentCurrent management of pruritusNonpharmacologic interventionsPharmacologic agentsStrategies to optimize assessment and management of pruritusCollaborative careDevelopment of a treatment planOngoing assessment and adjustment of therapyResources and support for patientsPresenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBCLink to full program: https://bit.ly/3Dnfb2E
In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with primary biliary cholangitis (PBC), discuss the burden of pruritus in PBC and the impact it has on quality of life, including both physical and mental health, from a patient's perspective. Presenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBC Link to full program: https://bit.ly/4gDGDaB
In this episode, Jean-Michel Molina, MD, PhD, and Joseph J. Eron, Jr., MD, discuss results from key clinical trials on HIV prevention and treatment as well as sexually transmitted infection (STI) prevention presented at IDWeek and Glasgow 2024, including:PURPOSE 1 and 2 comparing lenacapavir injection vs oral TDF/FTCTRIO Health Cohort and OPERA examining long-acting cabotegravir as PrEPDOLCE comparing DTG/3TC as first-line therapy in treatment-naive patients with HIVPRIDOX evaluating the use of DoxyPEP on STI incidence in men who have sex with men on PrEPPresenters:Jean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and lariboisièreParis, FranceJoseph J. Eron, Jr., MDProfessor of Medicine, School of MedicineHerman and Louise Smith Distinguished ProfessorChief, Division of Infectious DiseasesDirector, Clinical Core, UNC Center for AIDS ResearchAdjunct Professor of Epidemiology, Gillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaLink to full program: https://bit.ly/3BBaZvJ
Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.Launch Date: December 12, 2024Release Date: December 12, 2024Expiration Date: November 30, 2025FACULTYGuy Young, MDProfessor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips-in-hemophilia-cutting-edge-advances-presented-at-ash-2024-1
Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. Patients continue to face challenges related to symptom control, mental health, and the long-term impacts of both the disease and its treatments. Additionally, there is a critical need for improved global access to care, multidimensional support, and advocacy. In this podcast episode, Dr. Jean Elwing and Dr. Oksana Shlobin discuss these gaps by focusing on the latest updates from the 7th World Symposium on Pulmonary Hypertension (WSPH), offering insights into the latest clinical classifications, risk stratifications, and treatment strategies.This podcast aims to enhance clinical practice by presenting key research findings, new treatment algorithms, and the implications of emerging therapies. The discussion will include advances in multimodality imaging, genetics, and right ventricular function, highlighting how these innovations improve PH diagnosis and patient management. Through an expert-led presentation and interactive Q&A session, participants will gain a comprehensive understanding of how these developments will shape future research and personalized care for PH patients.Launch Date: November 19, 2024Release Date: November 19, 2024Expiration Date: October 31, 2025FACULTYJean Elwing, MDProfessor of MedicineDirector, Pulmonary Hypertension ProgramUniversity of CincinnatiOksana Shlobin, MDMedical Director, Pulmonary Hypertension ProgramDirector of Education and Outreach, Advanced Lung Disease ProgramInova Fairfax HospitalThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-pah-updates-from-the-7th-world-symposium-on-pulmonary-hypertension-1
These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' podcast episodes from data presented during IDWeek 2024.Launch Date: October 23, 2024Release Date: October 23, 2024Expiration Date: September 30, 2025FACULTYJoseph Eron, MDProfessor of MedicineUniversity of North Carolina at Chapel HillThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-idweek-2024-1
These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' podcast episodes from data presented during IDWeek 2024.Launch Date: October 23, 2024Release Date: October 23, 2024Expiration Date: September 30, 2025FACULTYJoseph Eron, MDProfessor of MedicineUniversity of North Carolina at Chapel HillThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-idweek-2024-1
Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In this podcast series, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand audio presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.Launch Date: October 14, 2024Release Date: October 7, 2024Expiration Date: September 30, 2025FACULTYSteven Nathan, MDMedical Director, Advanced Lung Disease and Transplant ProgramInova Fairfax HospitalJean Elwing, MDProfessor of MedicineDirector, Pulmonary Hypertension ProgramUniversity of CincinnatiIoana Preston, MDAssociate Professor of MedicineTufts University School of MedicineThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/expert-guided-strategies-to-improve-recognition-diagnosis-and-treatment-of-ph-associated-with-ild-1
Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In this podcast series, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand audio presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.Launch Date: October 14, 2024Release Date: October 7, 2024Expiration Date: September 30, 2025FACULTYSteven Nathan, MDMedical Director, Advanced Lung Disease and Transplant ProgramInova Fairfax HospitalJean Elwing, MDProfessor of MedicineDirector, Pulmonary Hypertension ProgramUniversity of CincinnatiIoana Preston, MDAssociate Professor of MedicineTufts University School of MedicineThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/expert-guided-strategies-to-improve-recognition-diagnosis-and-treatment-of-ph-associated-with-ild-1
Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In this podcast series, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand audio presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.Launch Date: October 14, 2024Release Date: October 7, 2024Expiration Date: September 30, 2025FACULTYSteven Nathan, MDMedical Director, Advanced Lung Disease and Transplant ProgramInova Fairfax HospitalJean Elwing, MDProfessor of MedicineDirector, Pulmonary Hypertension ProgramUniversity of CincinnatiIoana Preston, MDAssociate Professor of MedicineTufts University School of MedicineThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/expert-guided-strategies-to-improve-recognition-diagnosis-and-treatment-of-ph-associated-with-ild-1
Clinicians often encounter patients having complex clinical scenarios when managing PH where diverse and dynamic diagnostic and therapeutic issues interact. In this podcast episode, Dr. De Marco and Dr. Oudiz discuss complex clinical case scenarios to improve knowledge of the diagnosis and management of hypertension and its application in practice.Launch Date: September 4, 2024Release Date: September 4, 2024Expiration Date: August 31, 2025FACULTYRonald J. Oudiz, MD, FACP, FACC, FCCPChief, Division of CardiologyProfessor of MedicineThe David Geffen School of Medicine at UCLADirector, Pulmonary Hypertension ClinicHarbor-UCLA Medical CenterTeresa De Marco, MDProfessor of Medicine; R.H. and Jane G. Logan Endowed Chair in CardiologyUniversity of California, San FranciscoMedical Director Heart TransplantationBurlingame, CaliforniaThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-pah-navigating-clinical-challenges-through-case-studies-of-complex-scenarios-12
In this episode, Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD; Marlyn J. Mayo, MD; and Brenda Remo discuss the patient experience with cholestatic pruritus in PBC.Listen to their conversation on how people describe the experience of cholestatic pruritus, the extent to which pruritus negatively affects quality of life, and the importance of educating healthcare professionals on this important symptom of PBC.Presenters:Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford Health Detroit, MichiganMarlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUniversity of Texas SouthwesternDallas, TexasBrenda RemoPerson living with PBCDownloadable slides: https://bit.ly/3LHHiufProgram: https://bit.ly/4fBLQ3lTo get access to all of our new podcast episodes, subscribe to the CCO podcast channels on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD; Marlyn J. Mayo, MD; and Brenda Remo discuss strategies for optimizing PBC pruritus care in the clinic setting.Listen to their conversation on how important it is to ask patients about their pruritus, validate their symptoms and feelings, and offer treatment options framed with realistic expectations.Presenters:Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford Health Detroit, MichiganMarlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUniversity of Texas SouthwesternDallas, TexasBrenda RemoPerson living with PBCDownloadable slides: https://bit.ly/3LHHiufProgram: https://bit.ly/4fBLQ3lTo get access to all of our new podcast episodes, subscribe to the CCO podcast channels on Apple Podcasts, Google Podcasts, or Spotify.
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:Prognostic variables when deciding between regimensRole of MRD in CLLResults from the phase II CAPTIVATE trialChoosing among the available covalent BTK inhibitorsPreferred partner anti-CD20 antibody in CLL/SLLRole of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLLUse of CAR T-cell therapy in CLL/SLLPresenters:Farrukh Awan, MDProfessor of Internal MedicineDirector of Lymphoid Malignancies ProgramHarold C. Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallas, TexasJeremy S. Abramson, MD, MMScDirector, Center for LymphomaMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsShuo Ma, MD, PhDProfessor of MedicineDivision of Hematology-OncologyDepartment of MedicineRobert H. Lurie Comprehensive Cancer CenterNorthwestern University Feinberg School of MedicineChicago, IllinoisContent based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.Link to full program:https://bit.ly/3LzA2As
This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA 2024) Hybrid Congress, June 13-16, Madrid, Spain.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC credit.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025Faculty BioJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector of the Center of Excellencefor Blood Cancers and Myeloid DisordersNew York, New YorkThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/podcast-from-eha-2024-advancements-in-myelofibrosis-from-pathophysiology-to-personalized-treatment-strategies
Jointly Provided by American Academy of CME and CheckRare CE.Supported by educational grants from argenx US, Inc. and UCB Inc.To claim credit for this program, please visit https://checkrare.com/learning/p-myasthenia-gravis-research-highlights-aan-2024/Estimated time to complete: 0.5 hoursStart date: June 15, 2024End date: June 30,2025Activity DescriptionThis accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.Treatment of myastheniagravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient's comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as well as real world data, were presented at the American Academy of Neurology Annual Meeting (AAN 2024) held in Denver, CO.This CME activity, hosted by Nicholas Silvestri, MD, of the University of Buffalo, provides an overview of the latest clinical research presented at AAN 2024 focused on myasthenia gravis.Activity FacultyNicholas Silvestri, MDProfessor of NeurologyUniversity of Buffalo Jacobs School of Medicine and Biomedical SciencesTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology, and general practice. Other members of the care team may also participate.Learning ObjectiveAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage people with myasthenia gravis and its clinical relevanceAccreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Silvestri discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: argenx, Alexion, UCB, Immunovant, Janssen, AmgenSpeakers Bureau: argenx, Alexion, UCB, TakedaPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. American Academy of CME and CheckRare CE. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients.Launch Date: May 30, 2024Release Date: May 30, 2024Expiration Date: April 30, 2025FACULTY BIOAndrew Armstrong, MD, ScM, FACPProfessor of Medicine, Surgery, Pharmacology and Cancer BiologyDuke UniversityTanya Dorff, MDProfessor of MedicineCity of HopeThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8
This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients.Launch Date: May 30, 2024Release Date: May 30, 2024Expiration Date: April 30, 2025FACULTY BIOAndrew Armstrong, MD, ScM, FACPProfessor of Medicine, Surgery, Pharmacology and Cancer BiologyDuke UniversityTanya Dorff, MDProfessor of MedicineCity of HopeThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8
This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC podcasts will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients.Launch Date: May 30, 2024Release Date: May 30, 2024Expiration Date: April 30, 2025FACULTY BIOAndrew Armstrong, MD, ScM, FACPProfessor of Medicine, Surgery, Pharmacology and Cancer BiologyDuke UniversityTanya Dorff, MDProfessor of MedicineCity of HopeThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/talking-prostate-cancer-homologous-recombination-repair-gene-mutation-testing-in-metastatic-prostate-cancer-8
In this episode, Maria Buti, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including: Barriers to HBV screening, including patient- and provider-specific barriers (eg, lack of education, failure to disclose or discuss risk factors, perceived low risk, stigma)Applying CDC recommendations for universal HBV screening in adults Strategies to improve HBV transitions of care (eg, improved education, simplify criteria for screening and monitoring, alternative testing sites)Importance of testing close contacts for HBV after initial diagnosis and promoting HBV vaccination Presenter: Maria Buti, MDProfessor of MedicineSenior ConsultantLiver UnitHospital Universitario Valle HebronBarcelona, SpainContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/49TuZ8UGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Joseph J. Eron, Jr., MD, and Monica Gandhi, MD, MPH, discuss the key HIV studies from CROI 2024 that are influencing their clinical practice, including:New data surrounding long-acting ART, including:The CARES study of LA CAB + RPV in a Sub-Saharan African population using a public health approachThe IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIVThe ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ARTUpdated data from San Francisco's Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baselineCase series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV aloneData on comorbidities and coinfections, including:A REPRIEVE proteomic analysis to elucidate mechanistic pathways of statin effects on plaqueThe ACTG A5371 SLIM LIVER study of semaglutide for MASLD in people living with HIVThe impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San FranciscoPotential novel treatment options on the horizon for people living with HIV, including:Phase II data on LEN + ISL dosed orally once weeklyEarly data on other oral weekly optionsData on bNAbs in combination or with other ART agentsPresenters:Joseph J. Eron, Jr., MDProfessor of Medicine, School of MedicineHerman and Louise Smith Distinguished ProfessorChief, Division of Infectious DiseasesDirector, Clinical Core, UNC Center for AIDS ResearchAdjunct Professor of EpidemiologyGillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineMedical Director, Ward 86 HIV ClinicUniversity of California, San FranciscoSan Francisco, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.Link to full program: https://bit.ly/4awdWJMGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:Challenges with the pathologic testing for HER2-low expressionOptimal treatment of patients with HER2-low advanced breast cancerRole of TROP-2–targeted therapiesManagement of ADC-associated adverse events to optimize treatment outcomesADCs on the horizon for patients with advanced breast cancerPresenters:Sara M. Tolaney, MD, MPHChief, Division of Breast OncologyDana-Farber Cancer InstituteAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsMelinda Telli, MDProfessor of MedicineStanford University School of MedicineDirector, Breast Cancer ProgramStanford Cancer InstitutePalo Alto, CaliforniaContent based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.Link to full program:https://bit.ly/49WxRBM
Ozlem Goker-Alpan, MD of LDRTC and John Bach, MD, Professor of Neurology at Rutgers School of Medicine discuss best practices to manage respiratory complications in persons with lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees. To receive credit for this program, visit https://checkrare.com/learning/p-ldrtc2023-webinar3-assessing-monitoring-managing-respiratory-involvement-in-lysosomal-disorders/DisclosuresAffinityCE staff, LDRTC staff, CheckRare staff, planners, and reviewers, have no relevant financial interests to disclose. All faculty disclosures are listed below and are included in the beginning of each presentation.Ozlem Goker-Alpan, MDFounder and President, Lysosomal & Rare Disorders Research & Treatment Center (LDRTC).Dr. Goker-Alpan is a consultant, a principal investigator and /or on the speaker bureau, or has received grant support, from the following pharmaceutical companies: Actelion, Amicus Therapeutics, Sanofi, Takeda, Pfizer/Protalix.John Bach, MDProfessor of Physical Medicine and Rehabilitation, Professor of Neurology, Rutgers New Jersey Medical Center.Dr. Bach has no relevant financial interest to disclose.Mitigation of Relevant Financial Relationships AffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Learning ObjectivesAt the end of this activity, participants should be able to:• Describe the most common LSDs that have pulmonary complications. • Describe best practices to manage pulmonary symptoms in Pompe disease. • Describe best practices to manage pulmonary symptoms in MPSs.• Describe best practices to manage sleep apnea in lysosomal diseases.PhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesContinuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1.25 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic Counselors Category 2 CEUAffinityCE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Genetic counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.Commercial Support Support for this educational activity was provided by Takeda, Sanofi, Amicus Therapeutics and Chiesi USA. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.com.Send customer support requests to cds_support+ldrtc@affinityced.com.
In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss how to optimize the use of COVID-19 antivirals and how to navigate drug-drug interactions between COVID-19 treatments and a patient's home medications. Their discussion includes:Current COVID-19 landscapeCOVID-19 testing and vaccination recommendationsTreatment guidelines and antiviral options for nonhospitalized adults with COVID-19Resources for assessing and managing COVID-19 antiviral-related drug-drug interactionsAnswers to learners' most pressing questionsPresenters:Renslow Sherer, MDProfessor of MedicineSection of Infectious Diseases and Global HealthUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of PharmacyEmory University Hospital MidtownAtlanta, GeorgiaSlideset: https://bit.ly/4c6kwbJDownloadable resource:https://bit.ly/49rofP6Full program: https://bit.ly/3P16TR8Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
In this episode, Jennifer Green, MD, and Carol Hatch Wysham, MD, break down the latest headlines on incretin-based therapies and how to address these topics with patients. Their discussion includes:Beneficial effects beyond glycemic control Adverse events and how to manage themNon- or partial responders and the importance of setting expectations with patients Weight rebound when discontinuing therapyMedication access issues related to cost and drug availability Presenters:Jennifer Green, MDProfessor of MedicineDivision of Endocrinology and Duke Clinical Research InstituteDuke University School of MedicineDurham, North CarolinaCarol Hatch Wysham, MDClinical Professor of MedicineClinical EndocrinologistMultiCare/Rockwood ClinicSpokane, WashingtonLink to online program: https://bit.ly/48b6XnW
In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:Current therapiesStudies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDFKaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis BEarly vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV TransmissionInvestigational functional cure strategiesB-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV InfectionMARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV InfectionREEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHBHBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV InfectionCVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV InfectionPresenter:Nancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical Center Chicago, IllinoisLink to full program: https://bit.ly/47XJlU4
This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).Launch Date: January 29, 2024Release Date: January 29, 2024Expiration Date: December 30, 2024FACULTY BIOSPrithviraj Bose, MDProfessor, Department of Leukemia, Division of Cancer MedicineUniversity of TexasMD Anderson Cancer CenterJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Center of Excellence in Blood Cancers and Myeloid DisordersRuben Mesa, MDExecutive DirectorAtrium Health Wake Forest Baptist Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conference-briefs-highlighting-myelofibrosis-clinical-data-from-key-conferences-17
This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).Launch Date: January 29, 2024Release Date: January 29, 2024Expiration Date: December 30, 2024FACULTY BIOSPrithviraj Bose, MDProfessor, Department of Leukemia, Division of Cancer MedicineUniversity of TexasMD Anderson Cancer CenterJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Center of Excellence in Blood Cancers and Myeloid DisordersRuben Mesa, MDExecutive DirectorAtrium Health Wake Forest Baptist Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conference-briefs-highlighting-myelofibrosis-clinical-data-from-key-conferences-17
This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).Launch Date: January 29, 2024Release Date: January 29, 2024Expiration Date: December 30, 2024FACULTY BIOSPrithviraj Bose, MDProfessor, Department of Leukemia, Division of Cancer MedicineUniversity of TexasMD Anderson Cancer CenterJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Center of Excellence in Blood Cancers and Myeloid DisordersRuben Mesa, MDExecutive DirectorAtrium Health Wake Forest Baptist Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conference-briefs-highlighting-myelofibrosis-clinical-data-from-key-conferences-17
In this episode, Nancy Reau, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus and hepatitis delta virus, including:The importance of patient education along the care continuumEnsuring smooth transitions of care and communication between medical teamsScreening hepatitis delta in persons with chronic hepatitis BManaging hepatitis delta, including considerations for clinical trialsPromoting patient advocacyPresenter: Nancy Reau, MDProfessor of Medicine Chief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: bit.ly/3SrMuGOGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Novel therapies targeting the immune system and their combinations are gaining ground in AML. This podcast series, led by expert faculty, will clarify the potential and utility of innovative therapies that harness the immune system and will provide guidance on their applicability into clinical practice, especially for elderly/unfit patients with AML. Launch Date: December 27, 2023Release Date: December 27, 2023Expiration Date: November 30, 2024FACULTY BIOSTapan Kadia, MDMD Anderson Cancer InstituteUniversity of TexasDaniel Pollyea, MDProfessor of MedicineUniversity of Colorado School of MedicineDepartment of HematologyEunice Wang, MDProfessor of OncologyChief, Leukemia/Benign Hematology ServiceDepartment of MedicineMedical Director, Chemo/Infusion ClinicsRosewell Park Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-acute-myeloid-leukemia-novel-therapies-targeting-the-immune-system-for-elderlyunfit-patients-1
Novel therapies targeting the immune system and their combinations are gaining ground in AML. This podcast series, led by expert faculty, will clarify the potential and utility of innovative therapies that harness the immune system and will provide guidance on their applicability into clinical practice, especially for elderly/unfit patients with AML. Launch Date: December 27, 2023Release Date: December 27, 2023Expiration Date: November 30, 2024FACULTY BIOSTapan Kadia, MDMD Anderson Cancer InstituteUniversity of TexasDaniel Pollyea, MDProfessor of MedicineUniversity of Colorado School of MedicineDepartment of HematologyEunice Wang, MDProfessor of OncologyChief, Leukemia/Benign Hematology ServiceDepartment of MedicineMedical Director, Chemo/Infusion ClinicsRosewell Park Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-acute-myeloid-leukemia-novel-therapies-targeting-the-immune-system-for-elderlyunfit-patients-1
Novel therapies targeting the immune system and their combinations are gaining ground in AML. This podcast series, led by expert faculty, will clarify the potential and utility of innovative therapies that harness the immune system and will provide guidance on their applicability into clinical practice, especially for elderly/unfit patients with AML. Launch Date: December 27, 2023Release Date: December 27, 2023Expiration Date: November 30, 2024FACULTY BIOSTapan Kadia, MDMD Anderson Cancer InstituteUniversity of TexasDaniel Pollyea, MDProfessor of MedicineUniversity of Colorado School of MedicineDepartment of HematologyEunice Wang, MDProfessor of OncologyChief, Leukemia/Benign Hematology ServiceDepartment of MedicineMedical Director, Chemo/Infusion ClinicsRosewell Park Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-acute-myeloid-leukemia-novel-therapies-targeting-the-immune-system-for-elderlyunfit-patients-1
During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including: A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)A study that evaluated the effectiveness and safety of second-line therapy in PBC where obeticholic acid with or without a fibrate was added to the treatment regimen of people with PBC with an incomplete response to UDCAA retrospective review of the rates of hyperlipidemia, atherosclerosis, and/or hepatic steatosis in patients with PBCPresenter: Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasLink to commentary:https://bit.ly/47PmGdcLink to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI
© 2020-2025 Ivy Podcast Discovery LLC
